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PCR-restriction fragment length poymorphism (PCR-RFLP) is a simple, robust technique for the rapid
identification of isoniazid-resistant Mycobacterium tuberculosis. One hundred consecutive isolates from a
Vietnamese tuberculosis hospital were tested by MspA1I PCR-RFLP for the detection of isoniazid-resistant
katG_315 mutants. The test had a sensitivity of 80% and a specificity of 100% against conventional phenotypic
drug susceptibility testing. The positive and negative predictive values were 1 and 0.86, respectively. None of
the discrepant isolates had mutant katG_315 codons by sequencing. The test is cheap (less than $1.50 per test),
specific, and suitable for the rapid identification of isoniazid resistance in regions with a high prevalence of
katG_315 mutants among isoniazid-resistant M. tuberculosis isolates.
Tuberculosis (TB) control is threatened by increasing resis-
tance to first-line antituberculous agents. The WHO estimates
that in the year 2004, 4.3% of new TB cases globally were
multidrug-resistant TB (MDR-TB) (29), defined as resistance
to at least isoniazid and rifampin. Treatment regimens for
MDR-TB are more complex, less potent, more toxic, and more
expensive than first-line regimens, resulting in poorer tolera-
bility and adherence and higher morbidity and mortality rates.
Early identification of drug-resistant and particularly MDR
strains is routine in developed low-prevalence countries, but
the methods are currently unavailable to and too costly for
resource-poor nations, where the burden of disease is greatest.
Early identification of MDR-TB is crucial in order to permit
the timely administration of appropriate drug regimens and
could potentially improve the efficacy of MDR treatment
schemes, such as directly observed treatment, short course-plus.
Isoniazid is a prodrug that is activated through cleavage by
catalase peroxidase, the product of the katG gene. The active
drug has a complex mode of action, which remains to be fully
elucidated but principally targets mycolic acid biosynthesis
pathways. Upregulation of the inhA gene product, an enoyl-
ACP reductase, can overwhelm the impact of isoniazid.
Resistance to isoniazid is achieved through mutations in the
katG gene, predominantly at codon 315, and in the inhA pro-
moter for the majority of isolates. Mutations in other genes,
such as ahpC and ndh, have been implicated in isoniazid re-
sistance, but their roles are not yet proven. A role for kasA
gene mutation in isoniazid resistance has recently been dis-
credited (7). Many isolates are isoniazid resistant without any
mutations in known target genes, and the mechanism of resis-
tance for these isolates remains obscure.
Phenotypic sensitivity testing of Mycobacterium tuberculosis
is time-consuming, requiring 2 to 4 weeks from primary spec-
imen in settings with rapid liquid culture systems, such as
BACTEC MGIT 960, and 6 to 8 weeks in settings with solid-
medium culture (14).
Several approaches to the rapid identification of isoniazid
resistance have been reported in the literature, including real-
time PCR (22), single-strand-conformation polymorphism analy-
sis (20), dot blots (25), chips (1, 13), and multiplex-allele-specific
PCR (MAS-PCR) (12).
The PCR-RFLP approach has several advantages; it is
cheap, robust, and simple to both perform and interpret, re-
quiring only basic PCR equipment.
MspA1I digestion for the identification of the katG_315
mutation, as discussed here, has been described previously (9,
24, 27). The MspA1I restriction enzyme step also allows the
detection of mutations other than katG_S315T at the 315
codon site, increasing the sensitivity of the test over MAS-PCR
and still giving a positive identification of both mutant and
wild-type genes. It does not detect the very rare katG_S315R
(AGC3CGC) mutation (6).
Commercial molecular hybridization tests, such as INNO-
LiPA RIF TB (Innogenetics, Zwijnaarde, Belgium) and
MDRTBI (Hain Lifesciences, Nehren, Germany), while sensi-
tive and specific (10), are too costly for routine use where the
burden of disease is greatest. Both of these tests are based on
reverse hybridization of a PCR product to membrane-bound
probes. The INNO-LiPA RIF TB test detects mutations in the
rpoB gene and consequently detects only rifampin resistance.
However, rifampin resistance can be used as a surrogate
marker of MDR-TB in many settings (21, 26). The MDRTBI
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test has probes targeted to both rpoB and katG mutations for
the positive identification of MDR strains.
The identification of isoniazid resistance in the absence of
rifampin resistance is important in settings where primary re-
sistance to both isoniazid and streptomycin is high. Dual resis-
tance to isoniazid and streptomycin, without MDR, has been
strongly associated with an increased risk of treatment failure
(odds ratio [OR]  4.9; 95% confidence interval [CI], 1.1 to
26) or relapse (OR  3.3; 95% CI, 1.2 to 8.5) and with ac-
quired MDR (OR  6.6; 95% CI, 1.4 to 32) on a standard
WHO regimen (2 months of streptomycin, rifampin, isoniazid,
and pyrazinamide; 6 months of isoniazid and ethambutol
[2SRHZ/6HE]) (17). Around 25% of primary isolates are iso-
niazid resistant in Ho Chi Minh City, and 15% are isoniazid
and streptomycin dual resistant (15).
The aim of the current study was to develop a rapid, simple
PCR-RFLP screening test for the identification of isoniazid
resistance from positive M. tuberculosis cultures. Previous se-
quencing data on isoniazid-resistant isolates from Vietnam
indicated that around 80% of isoniazid-resistant isolates could
be detected through katG_315 analysis, with katG_S315T be-
ing by far the most prevalent mutation (71%) (3). A restriction
enzyme test specific for digestion of the CMGCKG site, found
at wild-type katG_315, was therefore developed. The test was
expected to detect all the mutations at codon 315 previously
identified in Ho Chi Minh City: G944C (S315T), G944A
(S315N), G944T (S315I), A943G (S315G), and G944C/C945G
(S315T) (3). Rare isolates (1% of isoniazid-resistant isolates)
that lack the katG gene would not produce an amplicon in the
initial PCR (28).
To assess specificity, the PCR-RFLP was tested on 47 DNA
extracts from M. tuberculosis isolates with previously deter-
mined katG sequences (3). The test was 100% specific and was
therefore tested prospectively on 100 positive M. tuberculosis
cultures collected from patients at the Pham Ngoc Thach Hos-
pital for Tuberculosis and Lung Diseases (PNT TB hospital),
Ho Chi Minh City.
The costs of the test in routine use were also calculated,
based on minimum equipment requirements, costs of reagents
available locally, and a batch size of 10 isolates.
MATERIALS AND METHODS
Sample collection. Initial testing was done on 47 cultures with known katG
gene sequences: 20 with S315T mutations, 20 isoniazid-sensitive isolates (wild-
type katG), 2 S315N, 2 S315I, 1 S315G, 1 S315T/T308T double mutant, and 1
isolate with a katG whole-gene deletion.
The test was then prospectively evaluated on 100 M. tuberculosis cultures from
pulmonary TB patients at the PNT TB Hospital during April 2006. An aliquot of
the first 20 isolates processed for phenotypic drug susceptibility testing each
Wednesday was also tested by PCR-RFLP. Drug susceptibility testing (DST) and
the PCR-RFLP test were performed blind by two different operators. The sen-
sitivity and specificity of the PCR-RFLP were determined at the end of the study.
Any isolate that produced discrepant results with the two tests was sequenced in
the katG gene to determine the katG_315 sequence.
DNA extraction. A single colony from culture was dispersed in 50 l distilled
water, and an equal volume of chloroform was added. The tube was vortexed,
heated at 80°C for 20 min, vortexed again, and centrifuged at 12,000  g for 5
min. Five microliters of the upper aqueous layer was taken for PCR. Three
control isolates were included with each run: one wild-type positive control, one
katG_S315T mutant positive control, and one negative control (water).
PCR. PCR of a 519-bp region of the katG gene was carried out with the
primers 5-GGTCGACATTCGCGAGACGTT-3 and 5-CGGTGGATCAGC
TTGTACCAG-3 from Marttila et al. (11). The reaction mixture had a final
concentration of 0.3 M each primer, 0.15 mM each deoxynucleoside triphos-
phate, and 3 mM MgCl2 with 0.75 U Taq per reaction (Bioline, United Kingdom)
(1 Bioline buffer supplied with enzyme). Five microliters of DNA extract was
added to 15 l reaction mixture, and the PCR was carried out in a Tetrad PCR
machine (Bio-Rad, United Kingdom) with the following program: 10 cycles of
15 s at 95°C, 1 min at 68°C, and 15 s at 72°C, followed by a further 25 cycles of
15 s at 95°C, 15 s at 68°C, and 15 s at 72°C.
Restriction enzyme digest. Ten microliters of restriction enzyme mixture was
added to each PCR mixture to give a final volume of 30 l containing a final 0.5
U of MspA1I (New England Biolabs), 0.7 New England Biolabs buffer 4
(supplied with enzyme), 100 g/ml bovine serum albumin according to the
manufacturer’s instructions. The mixture was incubated at 37°C for 2 h in the
PCR machine. The products were electrophoresed on a 1.5% agarose gel. A
309-bp band indicated a wild-type katG_315 codon. A 377-bp band indicated a
mutant type katG_ 315 codon and therefore izoniazid resistance (Fig. 1).
Phenotypic sensitivity testing. Phenotypic sensitivity testing for isoniazid re-
sistance was carried out at 0.2 g/ml by the 1% proportion method at the PNT
TB hospital, according to WHO protocols.
Sequencing. PCR products were amplified using primers as for the PCR-
RFLP test with a program of 30 cycles of 95°C for 15 s, 68°C for 15 s, and 72°C
for 15 s.
PCR products were purified with QIAgen PCR purification kits (QIAGEN,
United Kingdom) and then served as templates for cycle-sequencing reactions.
Both strands of each product were sequenced with CEQ Dye Terminator Cycle
Sequencing Quick Start kits (Beckman Coulter, Singapore) in half-volume reac-
tions using the same primers. The thermal-cycling program was 96°C for 20 s,
appropriate annealing temperature for 20 s, and 60°C for 4 min for 30 cycles,
followed by holding at 4°C. The cycle-sequencing products were subjected to
ethanol precipitation steps according to the manufacturer’s instructions and
sequenced on the CEQ8000 system (Beckman Coulter, Singapore).
MAS-PCR. MAS-PCR was used to screen for the inhA 15C3T mutation in
discrepant isolates. The primers were TB92 (3-CCTCGCTGCCCAGAAAGG
GA-5; 0.2 m) and TB93 (3-ATCCCCCGGTTTCCTCCGGT-5; 0.05 M)
from Telenti et al. (19a), with the internal primer inhA Rmut (5-AGTCACCC
CGACAACCTATTA-5; 0.25 M). The PCR mixture used 0.2 mM de-
oxynucleoside triphosphates, 2.5 mM MgCl2, 0.75 U Bioline Taq (Bioline,
United Kingdom), and 1 Taq buffer supplied by the manufacturer. Reaction
mixtures were amplified in a Tetrad PCR machine (MJ Research, Hercules,
Bio-Rad, United Kingdom), with an initial 2-min denaturation at 94°C, followed
FIG. 1. PCR-RFLP for the katG_315 mutation conferring isoniazid
resistance in M. tuberculosis. Lanes 1, 2, and 5, sensitive clinical iso-
lates; lanes 3 and 4, resistant clinical isolates; lane 6, sensitive control
(309-bp band); lane 7, resistant control (377-bp band); lane 8, 100-bp
ladder; lane 9, negative control.
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by 30 cycles of 30 s at 94°C, 15 s at 64°C, and 30 s at 72°C, with a final 2-min
elongation at 72°C.
The presence of two bands at 174 bp and 248 bp indicated a mutant allele
(inhA 15C3T). Wild-type isolates generated only a single band at 248 bp.
Costs. Cost calculations were based on a batch size of 10 isolates, with all
reagents purchased through local distributors and an exchange rate of 15,900
VND to the U.S. dollar. Equipment cost estimates were based upon locally
available catalogue prices. The cheapest appropriate models were selected for
calculations rather than the relatively expensive multiplate gradient models used
in our laboratory, as only a basic thermocycler is required to perform the test.
Costs were averaged and rounded up to the nearest $50. Final costs were
estimated in U.S. dollars.
RESULTS
Retrospective culture analysis. The test was 100% specific
for the detection of the katG_315 mutant codon on 47 retro-
spective cultures with known katG_315 sequences. The 20 iso-
niazid-sensitive isolates produced a wild-type 310-bp band, and
27 resistant isolates with miscellaneous mutations at katG_315
generated a 378-bp band (Fig. 1). The isolate with katG de-
leted failed to generate an amplicon, as predicted, and the
result was therefore “uninterpretable.” This DNA extract gen-
erated a product with other PCR-based tests, including spoli-
gotyping and rpoB and inhA sequencing (data not shown).
Prospective culture analysis. Of 100 M. tuberculosis cultures
tested at the PNT TB Hospital by PCR-RFLP, 35 were resis-
tant, 64 were wild type, and 1 isolate generated both wild-type
and resistant bands and was therefore deemed to be a mixed
culture.
By phenotypic DST, 43 isolates were resistant to isoniazid
(one of which was identified as Mycobacterium fortuitum), 55
were sensitive, and 2 failed to return a result due to failed
growth or contamination (both of which were sensitive by
PCR-RFLP). Excluding the two isolates that failed to return a
result by DST and the M. fortuitum isolate, the sensitivity of the
PCR-RFLP test was 80% and the specificity was 100%. The
positive predictive value and negative predictive value were 1
and 0.86, respectively.
Nine discrepant isolates were sequenced in the katG gene,
including seven isolates that returned a sensitive PCR-RFLP/
resistant DST result, one isolate (RE188) that returned a
mixed resistant/sensitive PCR-RFLP result with a resistant
DST result, and 1 isolate that returned a resistant PCR-RFLP
result but was identified as M. fortuitum by DST (RE180).
These isolates were also screened for the inhA 15C3T mu-
tation by MAS PCR. A summary of the discrepant isolates is
presented in Table 1.
The sequencing results confirmed that isolate RE180 con-
tained M. tuberculosis DNA and carried a katG_S315T muta-
tion. Isolate RE188 produced a heteropeak for the relevant
mutation at codon 315 (G944C/wild type), confirming that it
contained a mixed population of resistant and sensitive organ-
isms. The six remaining isolates carried a wild-type katG_315
codon, with one isolate (RE239) carrying a novel mutation in
katG, C1132A (L378M), confirming that in all these isolates
resistance was attributable to mutations at sites other than
katG_315.
The median time to positive culture was 32 days (range, 19
to 55 days; data were available for only 58 cultures). Pheno-
typic DST testing required a further 41 days to return a result,
with PCR-RFLP returning a result within 1 day.
Costs. The capital equipment required for the test consists
of a basic PCR machine (approximately $3,000), a gel tank
($550), a power pack ($1,600), a transilluminator ($1,000), a
camera ($400), and four pipettes ($1,000). The total capital
costs are approximately $7,550. However, this equipment can
also be used for other tests once it is purchased and is already
available in many reference level laboratories.
If 10 isolates are processed per batch, with three controls (a
positive mutant control, a positive wild-type control, and a
negative control), the cost of each test is $1.50 per isolate.
Labor costs were not included in this calculation.
DISCUSSION
The MspA1I PCR-RFLP rapid test described above showed
100% specificity and 80% sensitivity in the routine identifica-
tion of isoniazid-resistant M. tuberculosis. It is affordable and
simple to perform. It was also possible to obtain screening
results by PCR-RFLP for three isolates that failed to return
results by phenotypic DST due to failed regrowth or contam-
ination. Isolate RE180 was originally identified as M. fortuitum
at the PNT laboratory, and the presence of M. tuberculosis
DNA, shown by katG sequencing, in the original culture ex-
tract of isolate RE180 suggests that a laboratory contamination
event at the phenotypic DST subculture stage led to the growth
of M. fortuitum. However, it is impossible to rule out contam-
ination of an M. fortuitum sample with M. tuberculosis DNA
during PCR-RFLP sample processing for DNA extraction.
Unfortunately, clinical data were not available from the patient
to determine if M. tuberculosis was isolated from later samples.
The early detection of isoniazid resistance is an important
step in reducing the use of drug resistance-amplifying regi-
mens, particularly with the increasing availability of second-
line drugs through schemes such as DOTS-PLUS. Mutations in
katG_315 are associated with higher MICs for isoniazid than
mutations in the inhA promoter and therefore are probably of
greater clinical significance (18, 23, 24). Variations in the out-
comes of standard treatment regimens with a primary isoniazid-
resistant organism are multifactorial, but the MIC for the iso-
late may be a contributing factor.
Vietnam has an estimated primary isoniazid resistance rate
of 25% in Ho Chi Minh City (15). Despite having a well-
functioning National Tuberculosis Program (NTP) administer-
ing DOTS according to WHO guidelines (8), drug resistance
TABLE 1. katG gene sequences of isolates showing nine discrepant
results with PCR-RFLP and phenotypic DST
Isolate
no.
Result
PCR-RFLP DST katGsequencing
inhA 15C3T
MAS PCR
RE180 Resistant M. fortuitum S315T WT
RE188 Sensitive/resitant Resistant S315T/WTa WT
RE194 Sensitive Resistant WT 15C3T
RE207 Sensitive Resistant WT WT
RE220 Sensitive Resistant WT WT
RE227 Sensitive Resistant WT WT
RE239 Sensitive Resistant L378M 15C3T
RE250 Sensitive Resistant WT 15C3T
RE259 Sensitive Resistant WT WT
a Isolate RE188 showed a heteropeak (G/C) at katG_315, nucleotide 944. WT,
wild type.
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continues to rise. It has been speculated that this is due to high
rates of primary isoniazid resistance in conjunction with the
use of isonizid/ethambutol continuation phase regimens (16).
Of greatest concern is the evidence that this may be fueling the
development of MDR-TB, which has seen an increase from
2.3% in 1997 to an estimated 3.8% in 2005 (15). There is
therefore an urgent need for a cheap, rapid, simple test to
diagnose isoniazid resistance prior to the continuation phase,
when currently around 25% of patients in Vietnam effectively
receive monotherapy due to polyresistance. Primary isoniazid
resistance has been associated with the development of
MDR-TB after treatment (17). The katG_315 mutation is as-
sociated with the development and transmission of MDR-TB,
whereas other isoniazid resistance-conferring mutations, such
as inhA 15C3T, are not (7, 23, 24).
The test described here is economical ($1.50 per isolate) and
simple to perform. In routine laboratories, the cost per isolate
is likely to be lower, as we used a batch size of 10 isolates for
calculations whereas larger batch sizes of 20 to 30 could easily
be processed with careful precautions against contamination,
including the use of “clean” and “dirty” containment areas and
dUTPs with enzyme digestion and increasing the number of
negative controls in larger batches.
Currently, in the Vietnamese NTP, TB patients are tested
for drug resistance only after the microbiological failure of
first-line therapy. This is primarily because of cost and work-
load considerations. Although the PCR-RFLP test is not 100%
sensitive for the detection of isoniazid resistance, it is 100%
specific and can therefore be used as a rapid screening test to
identify the majority of patients with isoniazid-resistant organ-
isms. At $1.50 per test, it is also affordable. The test can be
completed in 1 day and requires around 2 to 3 h of hands-on
time if already-prepared PCR master mixtures are used. We
are currently evaluating the test for routine use directly with
smear-positive sputum.
Strategies for the rapid identification of drug resistance
should be region specific. A test screening for katG_315 mu-
tations is likely to be of the most use in regions with a high
prevalence of this mutation, such as China, Russia, the former
Soviet states, Vietnam, and Peru (3, 5). In Europe, a higher
prevalence of inhA gene mutations indicates that a multiplex
PCR or hybridization approach is warranted (2, 4, 19). The
reasons for variations in mutation prevalence are unclear and
may be related to TB control program differences or to varia-
tions in the predominant M. tuberculosis strains within a region.
Assessment of strategies for the rapid identification of drug
resistance should be made in the context of knowledge of the
predominant resistance-conferring mutations in a region.
In Vietnam, several factors should be considered: high un-
derlying isoniazid resistance, the rarity of rifampin resistance
without isoniazid resistance, and diverse rifampin resistance
mutation patterns complicating the identification of rifampin
resistance (3). These factors suggest an approach based upon
rapid isoniazid resistance screening, with subsequent rifampin
resistance testing in isoniazid-resistant isolates.
The implementation of rapid resistance-screening tests in
high-incidence areas must be carefully considered. In Vietnam,
as in many developing countries, patients whose primary ther-
apy fails are treated with a standard first-line retreatment reg-
imen. Even after identification of drug resistance by DST, TB
therapy is rarely modified, even though treatment success rates
with standard first-line drug retreatment regimens are known
to be low. The advent of DOTS-PLUS schemes supported by
the Green Light Committee for the economical procurement
of drugs makes the implementation of rapid drug resistance
screening and the use of second-line treatment regimes feasi-
ble within a well-established NTP such as is found in Vietnam.
The use of the PCR-RFLP test to rapidly identify isoniazid
resistance and to guide timely modification of therapy could
potentially reduce both the generation and transmission of
MDR-TB.
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